Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aceclofenac/diacerein/glucosamine - Jenburkt Pharmaceuticals

Next Previous
Drug Profile

Aceclofenac/diacerein/glucosamine - Jenburkt Pharmaceuticals

Alternative Names: Diacerein/aceclofenac/glucosamine; Glucosamine/aceclofenac/diacerein

Latest Information Update: 19 Feb 2016

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jenburkt Pharmaceuticals
  • Class Analgesics; Anthraquinones; Anti-inflammatories; Antirheumatics; Carbohydrates; Disease-modifying antirheumatics; Esters; Hexosamines; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Peripheral nervous system agents; Phenylacetates; Sensory system agents; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Interleukin 1 receptor antagonists; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Osteoarthritis

Most Recent Events

  • 19 Feb 2016 No development reported - Phase-III for Osteoarthritis in India (PO)
  • 05 Feb 2013 Jenburkt Pharmaceuticals completes a phase III trial in Osteoarthritis in India (CTRI2010-091-001092)
  • 15 Jul 2010 Phase-III clinical trials in Osteoarthritis in India (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top